On the 14th, it was found that nine patients who received the first treatment for COVID-19 in Korea showed improvement in their symptoms.
The Korea Centers for Disease Control and Prevention (KCDC) said on the 15th, “There are individual differences, but it has been confirmed that there are a large number of patients who are showing signs of improvement compared to before administration.”
A total of nine people were prescribed the treatment the day before Pfizer’s treatment, Paxrovid, began. All of them were at-home care, including 3 in Seoul, 3 in Daegu, 2 in Gyeonggi, and 1 in Daejeon.
The first person to take the drug is Mr. A, a man in his 70s living in Daejeon. On the 13th, he showed symptoms of COVID-19 such as cough and underwent a PCR test, and on the morning of the 14th he was confirmed and confirmed for home treatment.
A received non-face-to-face treatment at Daejeon Korea Hospital, a managed medical institution. The doctor inquired about his health condition and underlying diseases, checked the Drug Safety Use Service (DUR), confirmed that he was not taking contraindicated drugs, and decided to administer Paxrovid.
After that, the pharmacy dispensed the medicine and delivered the medicine directly to A.
The Central Accident Response Headquarters (Jungsubon) said, “According to the prescription of the medical staff and the medication guidance of the pharmacy, I received the medication, and after 1 to 2 hours at the managed medical institution, I checked whether the medication was administered and the state of health by wire.”
Paxrovid is effective only when taken within 5 days of symptom onset. Because the quantity is limited, for the time being, it will be prescribed for the elderly 65 years of age or older or those with mild to moderate symptoms with immunocompromised patients.
Over two days from the 14th to the 15th, 13,337 orders are being delivered nationwide. Most large cities will arrive on the 14th, and islands and mountainous areas will arrive within the same day.
◎ Sympathy Media News
[ⓒ 세계일보 & Segye.com, 무단전재 및 재배포 금지]
Source: 세계일보 by www.segye.com.
*The article has been translated based on the content of 세계일보 by www.segye.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!